ESMO 2022: Nivolumab + Ipilimumab Does Not Extend Disease-Free Survival in Kidney Cancer
Findings compared with placebo in patients with localized kidney cancer at high risk for relapse after nephrectomy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.